Glucagon-like peptide-1 receptor agonists (GLP-1RAs), once focused on treating diabetes and obesity, are now emerging as potential treatments for a broader range of chronic conditions, including metabolic dysfunction-associated steatohepatitis and Alzheimer’s disease.| Clinical Trials Arena